Supriya Lifescience Ltd

Supriya Lifesci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Supriya Lifescience Ltd

₹ 948 -0.44%
05 Jun - close price
supriyalifescience.com BSE: 543434 NSE: SUPRIYA
About

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]

Key Points

Niche Products Offerings[1]
Supriya Lifescience Ltd. has a niche product basket of 40+ APIs and is a global leader in Anti-histamines, anti-allergy, Vitamins, Anti-Asthmatics, & Anesthetics. They utilize a backward-integrated model for 15 products and possess the ability to handle complex chemistries and controlled substances.

Website BSE NSE
  • Market Cap ₹ 7,629 Cr.
  • Current Price ₹ 948
  • High / Low ₹ 1,086 / 546
  • Stock P/E 36.4
  • Book Value ₹ 149
  • Dividend Yield 0.11 %
  • ROCE 25.1 %
  • ROE 19.1 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Debtor days have increased from 79.6 to 96.8 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
142 132 140 140 158 161 166 186 184 145 200 206 277
87 88 108 99 103 98 101 120 117 93 127 134 179
Operating Profit 55 44 32 41 56 63 65 66 68 52 73 72 98
OPM % 39% 34% 23% 30% 35% 39% 39% 36% 37% 36% 36% 35% 35%
2 3 2 3 2 2 3 2 3 3 3 2 3
Interest 1 1 0 0 1 0 0 1 0 1 0 0 0
Depreciation 3 4 4 4 4 5 5 5 6 6 7 7 8
Profit before tax 53 43 30 40 53 60 62 63 64 47 68 67 92
Tax % 28% 33% 20% 26% 31% 25% 26% 25% 21% 27% 26% 26% 19%
38 29 24 30 37 45 46 47 50 35 50 50 74
EPS in Rs 4.75 3.54 2.97 3.70 4.59 5.55 5.73 5.81 6.26 4.32 6.27 6.17 9.22
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
184 213 278 312 391 530 461 570 696 828
166 191 213 213 218 316 332 394 436 534
Operating Profit 17 22 65 98 173 214 129 176 261 294
OPM % 9% 10% 23% 32% 44% 40% 28% 31% 37% 36%
7 9 8 11 5 8 9 11 10 11
Interest 12 11 10 7 4 4 3 5 2 2
Depreciation 5 5 5 6 7 10 12 16 20 28
Profit before tax 8 14 57 96 167 207 123 166 248 275
Tax % 30% 40% 31% 24% 26% 27% 27% 28% 24% 24%
6 9 39 73 124 152 90 119 188 209
EPS in Rs 3.87 5.96 26.93 50.11 16.89 18.86 11.17 14.80 23.35 25.98
Dividend Payout % 0% 0% 0% 20% 3% 3% 5% 5% 4% 4%
Compounded Sales Growth
10 Years: %
5 Years: 16%
3 Years: 22%
TTM: 19%
Compounded Profit Growth
10 Years: %
5 Years: 11%
3 Years: 33%
TTM: 11%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 56%
1 Year: 37%
Return on Equity
10 Years: 23%
5 Years: 20%
3 Years: 19%
Last Year: 19%

Balance Sheet

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 15 15 15 15 15 16 16 16 16 16
Reserves 31 40 79 134 254 600 683 799 981 1,182
140 130 90 82 72 27 22 5 5 5
55 60 69 105 105 92 98 101 110 154
Total Liabilities 241 245 253 336 445 735 820 921 1,112 1,357
89 91 85 99 100 190 262 310 453 689
CWIP 36 34 35 40 79 43 68 149 148 36
Investments 0 0 0 0 0 0 25 64 63 99
117 120 133 197 267 502 466 399 448 534
Total Assets 241 245 253 336 445 735 820 921 1,112 1,357

Cash Flows

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
27 28 49 117 76 49 64 113 165
-27 -5 5 -25 -47 -60 -124 -174 -152
-2 -20 -50 -29 -15 150 -10 -22 -8
Net Cash Flow -2 3 4 62 15 139 -70 -83 4
Free Cash Flow -0 23 54 92 29 -11 -44 -32 2
CFO/OP 158% 141% 97% 146% 61% 51% 73% 86% 86%

Ratios

Figures in Rs. Crores

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 99 92 79 60 69 79 67 71 70 97
Inventory Days 113 85 77 130 206 172 234 140 205 229
Days Payable 121 112 110 130 145 91 130 98 129 159
Cash Conversion Cycle 91 64 45 61 130 160 171 114 146 167
Working Capital Days -69 -50 -5 -40 28 117 168 157 144 147
ROCE % 14% 37% 50% 60% 43% 19% 22% 27% 25%

Insights

In beta
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Capacity Utilization
%

Log in to view insights

Please log in to see hidden values.

Login
Exports as % of Total Revenue
%
Installed Reactor Capacity
KLPD
Backward Integration Contribution to Revenue
%
Backward Integrated Products
Number
CEP (Certificates of Suitability)
Number
Global Footprint (Countries Presence)
Number
Revenue Contribution - Anesthetic Therapy
%
Total Customer Base
Number
USDMF (Active US Drug Master Files)
Number
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30%
5.73% 5.35% 4.56% 5.37% 4.95% 6.03% 6.52% 7.19% 6.78% 5.46% 5.19% 5.16%
7.54% 7.17% 5.39% 5.30% 5.48% 5.45% 4.93% 4.26% 4.86% 5.22% 5.00% 5.70%
18.43% 19.19% 21.77% 21.04% 21.27% 20.22% 20.25% 20.25% 20.08% 21.02% 21.49% 20.83%
No. of Shareholders 93,47892,99195,92987,98089,62185,32889,39491,05191,92887,91285,09981,161

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls